Group A Streptococcus sequencing reveals potential targets for a global vaccine


A collaborative research effort from scientists at the Wellcome Sanger Institute, the University of Cambridge (both Cambridge, UK), the Peter Doherty Institute for Infection and Immunity (Doherty Institute; Melbourne Australia) and the University of Queensland (Brisbane, Australia) has successfully characterized sequences from more than 2000 Group A Streptococcus samples, revealing potential sites for vaccine development.

The article, published in Nature Genetics, details these molecular targets amongst most strains, sourced from over 20 countries involved in the study. The importance of this work is undisputed considering the morbidity of Group A Streptococcus, termed ‘Strep A’, associated infections.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment